AMY-101 is under clinical development by Amyndas Pharmaceuticals and currently in Phase I for Glomerulonephritis. According to GlobalData, Phase I drugs for Glomerulonephritis have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMY-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
AMY-101 overview
AMY-101 (Cp-40) is under development for the treatment of PNH (Paroxysmal Nocturnal Hemoglobinuria), kidney transplantation, C3 glomerulonephritis, periodontitis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).The drug candidate acts by targeting complement C3. It is administered through subcutaneous or intravenous drip routes. The drug candidate is developed using technology for modulating the complement system.The drug candidate was also under development for the treatment of age related macular degeneration.
See Also:
For a complete picture of AMY-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
